Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M. Knauf WU, et al. Among authors: lissitchkov t. Br J Haematol. 2012 Oct;159(1):67-77. doi: 10.1111/bjh.12000. Epub 2012 Aug 4. Br J Haematol. 2012. PMID: 22861163 Free article. Clinical Trial.
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
Skotnicki A, Lissitchkov TJ, Mamonov V, Buevich E, Kuliczkowski K, Goranov S, Kłoczko J, Klukowska A, Stankovic S, Gercheva L, Chernova T, Hellmann A, Dmoszyńska A, Zawilska K, Veldman A, Joch C, Seifert W. Skotnicki A, et al. Among authors: lissitchkov tj. Thromb Res. 2016 Jan;137:119-125. doi: 10.1016/j.thromres.2015.10.014. Epub 2015 Oct 13. Thromb Res. 2016. PMID: 26614676 Clinical Trial.
Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
Lissitchkov TJ, Buevich E, Kuliczkowski K, Stasyshyn O, Cerqueira MH, Klukowska A, Joch C, Seifert W. Lissitchkov TJ, et al. Blood Coagul Fibrinolysis. 2017 Mar;28(2):152-162. doi: 10.1097/MBC.0000000000000568. Blood Coagul Fibrinolysis. 2017. PMID: 27203734 Free PMC article.
An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
Lissitchkov T, Klukowska A, Buevich E, Maltceva I, Auerswald G, Stasyshyn O, Seifert W, Rogosch T. Lissitchkov T, et al. J Blood Med. 2020 Oct 9;11:345-356. doi: 10.2147/JBM.S268907. eCollection 2020. J Blood Med. 2020. PMID: 33117020 Free PMC article.
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
Pasi KJ, Lissitchkov T, Mamonov V, Mant T, Timofeeva M, Bagot C, Chowdary P, Georgiev P, Gercheva-Kyuchukova L, Madigan K, Van Nguyen H, Yu Q, Mei B, Benson CC, Ragni MV. Pasi KJ, et al. Among authors: lissitchkov t. J Thromb Haemost. 2021 Jun;19(6):1436-1446. doi: 10.1111/jth.15270. Epub 2021 May 18. J Thromb Haemost. 2021. PMID: 33587824 Free PMC article. Clinical Trial.
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Windyga J, Timofeeva M, Stasyshyn O, Mamonov V, Lamas Castellanos JL, Lissitchkov T, Chojnowski K, Chapman M, Pavlova BG, Tangada S. Windyga J, et al. Among authors: lissitchkov t. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620946839. doi: 10.1177/1076029620946839. Clin Appl Thromb Hemost. 2020. PMID: 32816519 Free PMC article. Clinical Trial.
56 results